This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.
Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and
Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.
Expands innovative products business with non-steroidal therapy Crisaborole. Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema candidate. ... and if approved would be the first new non-steroidal
Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...